Aptorum Competitors
| APM Stock | USD 0.74 0.09 10.84% |
Aptorum Group vs Lyra Therapeutics Correlation
Poor diversification
The correlation between Aptorum Group Ltd and LYRA is 0.78 (i.e., Poor diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Aptorum Group Ltd and LYRA in the same portfolio, assuming nothing else is changed.
Moving together with Aptorum Stock
Moving against Aptorum Stock
| 0.86 | IMMP | Immutep Ltd ADR | PairCorr |
| 0.78 | ENGN | enGene Holdings Common | PairCorr |
| 0.74 | DSGN | Design Therapeutics | PairCorr |
| 0.58 | KYTX | Kyverna Therapeutics | PairCorr |
| 0.57 | 63E | ONWARD MEDICAL BV | PairCorr |
Aptorum Group Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Aptorum Group and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Aptorum and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Aptorum Group does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Aptorum Stock performing well and Aptorum Group Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Aptorum Group's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| MRKR | 5.31 | 1.05 | 0.19 | 0.53 | 5.05 | 12.79 | 28.69 | |||
| MBIO | 3.39 | (1.03) | 0.00 | (1.75) | 0.00 | 7.00 | 27.04 | |||
| CING | 3.29 | 0.88 | 0.17 | 0.91 | 4.21 | 7.46 | 20.08 | |||
| CLRB | 4.36 | (0.14) | 0.00 | (0.07) | 0.00 | 7.66 | 30.55 | |||
| IMRN | 4.23 | (1.10) | 0.00 | 1.34 | 0.00 | 5.88 | 36.62 | |||
| AEON | 4.40 | 0.61 | 0.09 | (1.10) | 5.30 | 10.34 | 33.74 | |||
| BOLT | 3.19 | (0.03) | 0.00 | (0.05) | 0.00 | 8.22 | 18.19 | |||
| COCP | 2.57 | (0.38) | 0.00 | (0.15) | 0.00 | 6.67 | 15.98 | |||
| EVGN | 2.55 | (0.15) | 0.00 | (0.24) | 0.00 | 4.20 | 21.74 | |||
| LYRA | 5.52 | (1.37) | 0.00 | (1.40) | 0.00 | 13.48 | 66.89 |
Cross Equities Net Income Analysis
Compare Aptorum Group and related stocks such as Marker Therapeutics, Mustang Bio, and Cingulate Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MRKR | (1.1 M) | (2 M) | (5.9 M) | (5.5 M) | (30.9 M) | (34.1 M) | (2.5 M) | (11 M) | (148 M) | (21.4 M) | (28.7 M) | (41.9 M) | (29.9 M) | (8.2 M) | (10.7 M) | (9.7 M) | (10.1 M) |
| MBIO | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (12.7 M) | (31.3 M) | (30.7 M) | (48.2 M) | (60 M) | (66.4 M) | (77.5 M) | (51.6 M) | (15.8 M) | (14.2 M) | (14.9 M) |
| CING | (11.5 M) | (11.5 M) | (11.5 M) | (11.5 M) | (11.5 M) | (11.5 M) | (11.5 M) | (11.5 M) | (11.5 M) | (11.5 M) | (7.2 M) | (20.7 M) | (17.9 M) | (23.5 M) | (15.5 M) | (14 M) | (14.7 M) |
| CLRB | (815.3 K) | (7.4 M) | (8.8 M) | (10.8 M) | (8.1 M) | (5.5 M) | (6.2 M) | (13.6 M) | (13.2 M) | (14.1 M) | (15.1 M) | (24 M) | (28.6 M) | (42.8 M) | (44.6 M) | (40.1 M) | (38.1 M) |
| IMRN | (1.6 M) | (2.3 M) | (3.5 M) | (2.7 M) | (2.7 M) | (7.1 M) | (6.8 M) | (3 M) | (4.7 M) | (2.9 M) | (8.4 M) | (2.9 M) | (3.8 M) | (6.9 M) | (5.2 M) | (4.7 M) | (4.9 M) |
| AEON | 172.9 M | 172.9 M | 172.9 M | 172.9 M | 172.9 M | 172.9 M | 172.9 M | 172.9 M | 172.9 M | 172.9 M | (32.9 M) | (55.6 M) | (52.6 M) | (384.6 M) | 42 M | 37.8 M | 39.7 M |
| BOLT | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (30.5 M) | (60.7 M) | (98.6 M) | (88.1 M) | (69.2 M) | (63.1 M) | (56.8 M) | (59.6 M) |
| COCP | (58.7 K) | (5.5 M) | (8 M) | (19.6 M) | (99 K) | (50.1 M) | (74.9 M) | (613 K) | (49 M) | (48.2 M) | (9.6 M) | (14.2 M) | (38.8 M) | (18 M) | (17.5 M) | (15.8 M) | (16.5 M) |
| EVGN | 645 K | 645 K | (2.5 M) | (8.9 M) | (14.5 M) | (17.2 M) | (19.6 M) | (20.8 M) | (20.8 M) | (18.1 M) | (23.4 M) | (27.8 M) | (26.6 M) | (23.9 M) | (16.5 M) | (14.8 M) | (15.6 M) |
| LYRA | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (16.3 M) | (22.1 M) | (42.4 M) | (55.3 M) | (62.7 M) | (93.4 M) | (84.1 M) | (79.9 M) |
Aptorum Group and related stocks such as Marker Therapeutics, Mustang Bio, and Cingulate Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Aptorum Group financial statement analysis. It represents the amount of money remaining after all of Aptorum Group Ltd operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Aptorum Group Competitive Analysis
The better you understand Aptorum Group competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Aptorum Group's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Aptorum Group's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Aptorum Group Competition Performance Charts
Five steps to successful analysis of Aptorum Group Competition
Aptorum Group's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Aptorum Group in relation to its competition. Aptorum Group's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Aptorum Group in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Aptorum Group's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Aptorum Group, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Aptorum Group position
In addition to having Aptorum Group in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Exotic Funds Thematic Idea Now
Exotic Funds
Funds or Etfs with high minimum investment requirement that manage portfolios of alternative investments such as hedge funds, options, futures, real estate or commodities. The Exotic Funds theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Exotic Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Aptorum Group Correlation with its peers. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Will Biotechnology sector continue expanding? Could Aptorum diversify its offerings? Factors like these will boost the valuation of Aptorum Group. If investors know Aptorum will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Aptorum Group data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
The market value of Aptorum Group is measured differently than its book value, which is the value of Aptorum that is recorded on the company's balance sheet. Investors also form their own opinion of Aptorum Group's value that differs from its market value or its book value, called intrinsic value, which is Aptorum Group's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Aptorum Group's market value can be influenced by many factors that don't directly affect Aptorum Group's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Aptorum Group's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Aptorum Group represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Aptorum Group's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.